BI30 An extensive follicular eruption in a transplant recipient

Sid Orpin,Bhavnisha Patel
DOI: https://doi.org/10.1093/bjd/ljae090.318
IF: 11.113
2024-06-28
British Journal of Dermatology
Abstract:Abstract A 46-year-old woman, who had been a patient with poorly controlled type 1 diabetes since age 18 years, received a combined pancreas and renal transplant in 2020. She was taking tacrolimus and mycophenolate as an immunosuppression regimen and presented with a 6-month history of an extensive rash. On examination, there was a widespread, symmetrical eruption affecting face, trunk and limbs consisting of folliculocentric pigmented keratinous papules. On the face and trunk in particular, these demonstrated a spiny appearance. Clinically, this was considered to be trichodysplasia spinulosa (TS), a rare dermatological condition first described in 1995 and established to be caused by TS-associated polyomavirus (TSPyV) in 2010. All cases are associated with either immunosuppressive medication or diseases that cause reduced immune function. Biopsies taken from the patient’s trunk and left thigh showed striking features of dilated follicles with prominent dyskeratosis and the follicular wall replaced by cells with grey cytoplasm and vesicular nuclei, alongside numerous homogeneous, eosinophilic intracytoplasmic inclusion bodies. These features have been described in only one case of a form of acquired epidermodysplasia verruciformis (EV) caused by type 49 human papillomavirus (HPV). More often, HPV-3, 4, 5, 8 and 51 are seen in EV. Subsequent use of SV40, an immunohistochemical stain that is a surrogate marker for polyomavirus infection, failed to demonstrate TSPyV, confirming the diagnosis as EV. There are currently no published case reports of acquired EV presenting in this way, simulating the follicle-centred spiculated rash seen exclusively in TS up to this point. EV, whether of inherited or acquired origin, presents either as a spreading eruption of pityriasis versicolor-like scaly macules, flat planar wart-like papules or verrucous seborrhoeic keratosis-like papules and plaques. Although the acquired form of EV does not appear to have the same risks of developing cutaneous squamous cell carcinomas as the inherited type, there is still an increased incidence of such tumours in transplant populations, so treating EV in our patient remains an important goal. Unfortunately, there are no established, effective treatment modalities. With less widespread lesions cryotherapy, topical imiquimod or topical 5-aminolaevulinic acid photodynamic therapy might be considered. In this case, with extensive disease, systemic treatment with oral retinoids, interferons or cimetidine could be considered but the results are unpredictable, and even when this treatment is effective at reducing the number of EV-related lesions, there is a high risk of recurrence upon cessation of therapy. In the first instance, following discussion with the renal team, it has been decided to cautiously reduce the doses of the patient’s immunosuppressive drugs as this is often effective in cases of TS.
dermatology
What problem does this paper attempt to address?